ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 22 of 101 for:    Recruiting, Not yet recruiting, Available Studies | "Blood Glucose"

Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00655460
Recruitment Status : Recruiting
First Posted : April 9, 2008
Last Update Posted : February 26, 2015
Sponsor:
Information provided by (Responsible Party):
Intermountain Health Care, Inc.

Brief Summary:

The Purpose of this study is to:

  1. Refine and validate a computerized bedside decision support tool blood glucose management in critically ill adult and pediatric ICU patients.
  2. Monitor how often low blood sugar levels occur during use of the bedside tool.
  3. Determine how the computerized tool effects the workload of the ICU nurses.

Condition or disease Intervention/treatment Phase
Critically Ill Hyperglycemia Procedure: glucose control with computer generated recommendations Phase 2

Detailed Description:
This first phase will be a prospective cohort study. We will validate the bedside tool in at least 4 adult and at least 4 pediatric ICUs and if necessary we will modify the bedside tool. The computerized bedside tool will be considered refined if >90% of the generated instructions are accepted and if the percent of glucose values in the 70-110 mg/dl range are equivalent to our pilot experience rate of 55%, and if the rate of glucose values less than or equal to 40 mg/dl is less than 0.5% of glucose measurements.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Process Improvement With A Bedside Computerized Insulin Therapy Protocol For Blood Glucose Control (eProtocol-insulin) in Adult And Pediatric ICU Patients:Further Refinement and Validation of eProtocol-insulin
Study Start Date : February 2006
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Sugar
Drug Information available for: Dextrose

Arm Intervention/treatment
Experimental: eProtocol Procedure: glucose control with computer generated recommendations
Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.




Primary Outcome Measures :
  1. The primary outcome variable during Phase I will be the acceptability of the eProtocol-insulin instructions (compliance of bedside clinicians with instructions: more than 90 % of all instructions accepted by the bedside clinician). [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Proportion of glucose determinations within the range of 70-110 mg/dl (3.9-6.1 mMol/l) [ Time Frame: 3 years ]
  2. Nursing perception of workload in comparison to ordinary care [ Time Frame: 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Month and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Pediatric ICU: Proposed indications by pediatric clinicians at participating ICUs for glucose control in their ICUs would include patients who require mechanical ventilation for greater than 24 hours and/or require a vasoactive infusion (e.g. dopamine >3 mg/kg/min, dobutamine, epinephrine, or vasopressin).
  2. Adult ICUs: Proposed indications by clinicians in participating ICUs for glucose control in participating adult ICUs include critically ill patients with an anticipated ICU length of stay of 3 or more days.

Exclusion Criteria:

  1. Pregnancy (negative pregnancy test required for females of child-bearing age)
  2. Age less than one month
  3. Inborn errors of metabolism that the clinician suspects will affect glucose homeostasis
  4. Acute or chronic liver disease with any documented episode of blood or plasma glucose <60 mg/dl within the 24 hours prior to study entry
  5. Diabetic Ketoacidosis (critically ill patients with insulin dependent diabetes not in ketoacidosis will be eligible if attending physicians intend to use intravenous insulin as part of ordinary care)
  6. Severe chronic liver disease (Child-Pugh score >10)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00655460


Contacts
Contact: Alan H Morris, MD 801-408-1610 Alan.Morris@intermountainmail.org

Locations
United States, Connecticut
Yale University Completed
New Haven, Connecticut, United States, 05520
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21205
Principal Investigator: Roy Brower, MD         
United States, Massachusetts
Massachusetts General Hospital Withdrawn
Boston, Massachusetts, United States, 02114
Baystate Medical Center Active, not recruiting
Springfield, Massachusetts, United States, 01199
United States, North Carolina
Wake Forest Medical Center Recruiting
Winston-Salem, North Carolina, United States, 27157
Principal Investigator: Robert D Hite, MD         
United States, Pennsylvania
Pennsylvania State Children's Hospital Completed
Hersey, Pennsylvania, United States, 17033
Children's Hospital of Philadelphia Completed
Philadelphia, Pennsylvania, United States, 19104
United States, Tennessee
Vanderbilt University Completed
Nashville, Tennessee, United States, 37232
United States, Utah
LDS Hospital Recruiting
Salt Lake City, Utah, United States, 84143
Principal Investigator: James Orme, MD         
Primary Children's Hospital Completed
Salt Lake City, Utah, United States, 84143
United States, Virginia
University of Virginia Active, not recruiting
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
Intermountain Health Care, Inc.
Investigators
Principal Investigator: Alan H Morris, MD Intermountain Medical Center, Murray, Utah

Responsible Party: Intermountain Health Care, Inc.
ClinicalTrials.gov Identifier: NCT00655460     History of Changes
Other Study ID Numbers: N01-HC-45210-1
HHSN268200425210C
First Posted: April 9, 2008    Key Record Dates
Last Update Posted: February 26, 2015
Last Verified: January 2008

Keywords provided by Intermountain Health Care, Inc.:
Glucose
Insulin
computer
critical care

Additional relevant MeSH terms:
Critical Illness
Hyperglycemia
Disease Attributes
Pathologic Processes
Glucose Metabolism Disorders
Metabolic Diseases
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs